{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:15:42Z","timestamp":1789240542633,"version":"build-2803163510"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0137390","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T14:11:12Z","timestamp":1442931072000},"page":"e0137390","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country"],"prefix":"10.1371","volume":"10","author":[{"given":"Gustavo Machado","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Vaz","family":"de Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaucia Helena","family":"Martinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Ant\u00f4nio","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suely Meireles","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"ref1","first-page":"15","article-title":"Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation","author":"MM Horowitiz","year":"2009"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2008.197","article-title":"Impact of comorbidity indexes on non-relapse mortality","volume":"22","author":"A Xhaard","year":"2008","journal-title":"Leukemia"},{"issue":"22","key":"ref3","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"TA Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"ME Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/01.mlr.0000124254.88292.a1","article-title":"Comparison of comorbidity indexes for patients with head and neck cancer","volume":"42","author":"JF Piccirillo","year":"2004","journal-title":"Med Care"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"ML Sorror","year":"2005","journal-title":"Blood"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2004-02-0545","article-title":"Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities","volume":"104","author":"ML Sorror","year":"2004","journal-title":"Blood"},{"issue":"13","key":"ref9","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"ML Sorror","year":"2007","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbmt.2009.11.008","article-title":"Comparison of two pre transplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC","volume":"16","author":"P Barba","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bmt.2009.236","article-title":"Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML","volume":"45","author":"ZY Lim","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ajh.23443","article-title":"The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation","volume":"88","author":"XD Mo","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2012-03-414573","article-title":"Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study","volume":"120","author":"R Raimondi","year":"2012","journal-title":"Blood"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2010-08-303263","article-title":"Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients","volume":"117","author":"AR Smith","year":"2011","journal-title":"Blood"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/pbc.23057","article-title":"Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant","volume":"57","author":"W Wood","year":"2011","journal-title":"Pediatr blood cancer"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.bbmt.2011.06.009","article-title":"The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation-investigation of potential limitations of the index","volume":"17","author":"N Birninger","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/bmt.2011.138","article-title":"Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hematopoietic progenitor cell transplantation","volume":"47","author":"SW Bokhari","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/bmt.2008.300","article-title":"Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center","volume":"43","author":"R Guilfoyle","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 3","key":"ref19","first-page":"S87","article-title":"Avalia\u00e7\u00e3o de comorbidades e do n\u00edvel s\u00f3cio-econ\u00f4mico em transplante de c\u00e9lulas-tronco hematopo\u00e9ticas\u2014Dados Preliminares","volume":"31","author":"AV Macedo","year":"2009","journal-title":"Rev Bras Hematol e Hemoter"},{"issue":"suppl 1","key":"ref20","first-page":"S84","article-title":"Hematopoietic cell transplantation comorbidity index (HCT-CI) as a tool to predict non relapse mortality after allogeneic high dose conditioning hematopoietic stem cell transplantation (HSCT)","volume":"33","author":"MP Colella","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"P Armand","year":"2012","journal-title":"Blood"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"A Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"S Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"GB Mcdonald","year":"1984","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"H Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"AH Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Y. Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2014-01-550566","article-title":"Pre-transplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality","volume":"124","author":"ML Sorror","year":"2014","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbmt.2013.10.021","article-title":"Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome","volume":"20","author":"VT Potter","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2010-12-327536","article-title":"Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia","volume":"118","author":"JC Marsh","year":"2011","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-011-1299-8","article-title":"Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials","volume":"91","author":"YJ Chang","year":"2012","journal-title":"Ann Hematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.leukres.2011.10.016","article-title":"Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: Meta-analysis of randomized controlled trials","volume":"36","author":"H Zhang","year":"2012","journal-title":"Leuk Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0137390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T08:22:36Z","timestamp":1540023756000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0137390"}},"subtitle":[],"editor":[{"given":"Senthilnathan","family":"Palaniyandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0137390","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]}}}